As direct-to-patient (DTP) models reshape how therapies reach patients, the true differentiator will no longer be access alone — it will be adherence. While programs like LillyDirect and PfizerForAll simplify the path to therapy, the next phase demands real-time engagement, context, and continuity. Synchronyx’s Tappt platform transforms each prescription into a digital companion that tracks adherence, captures real-world barriers, connects patients to timely care, and turns every refill into proof of value.